A Phase 2 Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Advanced Melanoma

Full Title

A Phase 2 study of Fianlimab, Cemiplimab, and Ipilimumab in Anti-PD-1 Refractory Melanoma

Purpose

The purpose of this study is to see if the combination of fianlimab, cemiplimab, and ipilimumab works well against melanoma. The people in this study have melanoma that is inoperable (cannot be taken out with surgery) or metastatic (spread). In addition, their cancer keeps growing even after treatment that included immunotherapy.

Combining fianlimab, cemiplimab, and ipilimumab may work well against melanoma because each drug blocks different proteins that make tumors grow. Because they work in different ways, giving them together may be better than any of the three drugs given alone. This drug combination has been shown to shrink or halt the growth of melanoma in a small number of people. The drugs are given intravenously (by vein).

Contact

For more information or to see if you can join this study, please call Dr. James Smithy’s office at 646-888-6782.